Cargando…
Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study
BACKGROUND: Cefazolin is a commonly used antibiotic for the treatment of mild to severe infections. Despite the use of higher dose of cefazolin (3 g/dose) for surgical prophylaxis in patients with obesity, there is currently a paucity of data identifying the optimal dose to treat infections in this...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946698/ https://www.ncbi.nlm.nih.gov/pubmed/35350175 http://dx.doi.org/10.1093/ofid/ofac105 |
_version_ | 1784674255290499072 |
---|---|
author | Ryu, HaYoung Mohayya, Sana Hong, Thomas Modi, Mansi Yang, Jaehee Abdul Azim, Ahmed Bhatt, Pinki J Brunetti, Luigi Narayanan, Navaneeth |
author_facet | Ryu, HaYoung Mohayya, Sana Hong, Thomas Modi, Mansi Yang, Jaehee Abdul Azim, Ahmed Bhatt, Pinki J Brunetti, Luigi Narayanan, Navaneeth |
author_sort | Ryu, HaYoung |
collection | PubMed |
description | BACKGROUND: Cefazolin is a commonly used antibiotic for the treatment of mild to severe infections. Despite the use of higher dose of cefazolin (3 g/dose) for surgical prophylaxis in patients with obesity, there is currently a paucity of data identifying the optimal dose to treat infections in this specific patient population. METHODS: This was a multicenter, retrospective cohort study of patients who received cefazolin at weight-based (up to 9 g/day) or standard doses (up to 6 g/day) for the treatment of bacteremia or skin and soft tissue infection (SSTI). Study groups were stratified by body weight and cefazolin dose received. Primary outcome was the composite of treatment-emergent adverse events (TEAEs) and secondary outcome was treatment failure rate. RESULTS: A total of 208 patients were included for study analysis. Fifty-nine patients had body weight >120 kg. Of these, 33 received high-dose cefazolin while 26 received standard doses. The remaining 149 patients had body weight of ≤120 kg and received standard doses. The occurrence of TEAEs did not differ across the 3 groups. The study also did not find any difference between the rate of treatment failure between groups. CONCLUSIONS: High-dose cefazolin (9 g/day) for the treatment of bacteremia or SSTIs in patients with high body weight was safe and well tolerated. Larger studies are needed to further explore the benefit of high-dose cefazolin in improving clinical outcomes. |
format | Online Article Text |
id | pubmed-8946698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-89466982022-03-28 Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study Ryu, HaYoung Mohayya, Sana Hong, Thomas Modi, Mansi Yang, Jaehee Abdul Azim, Ahmed Bhatt, Pinki J Brunetti, Luigi Narayanan, Navaneeth Open Forum Infect Dis Major Article BACKGROUND: Cefazolin is a commonly used antibiotic for the treatment of mild to severe infections. Despite the use of higher dose of cefazolin (3 g/dose) for surgical prophylaxis in patients with obesity, there is currently a paucity of data identifying the optimal dose to treat infections in this specific patient population. METHODS: This was a multicenter, retrospective cohort study of patients who received cefazolin at weight-based (up to 9 g/day) or standard doses (up to 6 g/day) for the treatment of bacteremia or skin and soft tissue infection (SSTI). Study groups were stratified by body weight and cefazolin dose received. Primary outcome was the composite of treatment-emergent adverse events (TEAEs) and secondary outcome was treatment failure rate. RESULTS: A total of 208 patients were included for study analysis. Fifty-nine patients had body weight >120 kg. Of these, 33 received high-dose cefazolin while 26 received standard doses. The remaining 149 patients had body weight of ≤120 kg and received standard doses. The occurrence of TEAEs did not differ across the 3 groups. The study also did not find any difference between the rate of treatment failure between groups. CONCLUSIONS: High-dose cefazolin (9 g/day) for the treatment of bacteremia or SSTIs in patients with high body weight was safe and well tolerated. Larger studies are needed to further explore the benefit of high-dose cefazolin in improving clinical outcomes. Oxford University Press 2022-02-28 /pmc/articles/PMC8946698/ /pubmed/35350175 http://dx.doi.org/10.1093/ofid/ofac105 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Ryu, HaYoung Mohayya, Sana Hong, Thomas Modi, Mansi Yang, Jaehee Abdul Azim, Ahmed Bhatt, Pinki J Brunetti, Luigi Narayanan, Navaneeth Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study |
title | Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study |
title_full | Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study |
title_fullStr | Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study |
title_full_unstemmed | Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study |
title_short | Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study |
title_sort | safety and effectiveness of high-dose cefazolin in patients with high body weight: a retrospective cohort study |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946698/ https://www.ncbi.nlm.nih.gov/pubmed/35350175 http://dx.doi.org/10.1093/ofid/ofac105 |
work_keys_str_mv | AT ryuhayoung safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy AT mohayyasana safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy AT hongthomas safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy AT modimansi safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy AT yangjaehee safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy AT abdulazimahmed safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy AT bhattpinkij safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy AT brunettiluigi safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy AT narayanannavaneeth safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy |